Cholangiohepatitis

Cholangiohepatitis is an inflammatory condition of the liver that primarily involves the biliary tree (cholangitis) and extends into the adjacent hepatic parenchyma (hepatitis). It is a common cause of hepatic disease in cats, and less frequently in dogs. The disease is classified based on the duration and histologic pattern into acute (suppurative) and chronic (lymphocytic or lymphoplasmacytic) forms. In cats, it is often associated with inflammatory bowel disease (IBD) and pancreatitis, forming the 'triaditis' complex. The condition can lead to progressive fibrosis, cirrhosis, and hepatic failure if untreated. Cholangiohepatitis is characterized by infiltration of inflammatory cells into the portal tracts and bile ducts, with potential for bile duct obstruction and cholestasis.

The exact etiology of cholangiohepatitis is often unknown, but several factors are implicated. In cats, bacterial infection, particularly with enteric organisms such as Escherichia coli, Enterococcus spp., and anaerobic bacteria (e.g., Clostridium spp.), is a common trigger, often ascending from the gastrointestinal tract via the biliary system. Viral agents, such as feline coronavirus (FCoV) and feline leukemia virus (FeLV), have been suggested but not definitively proven. Parasitic infections, including liver flukes (Platynosomum concinnum) in tropical regions, can cause cholangiohepatitis. In dogs, leptospirosis (Leptospira interrogans) is a notable bacterial cause. Immune-mediated mechanisms are also proposed, especially in chronic lymphocytic cholangiohepatitis, where an aberrant immune response to dietary antigens or bacterial products may occur. Toxins and drugs, such as certain antibiotics or anti-inflammatory drugs, can induce hepatobiliary injury. Genetic predisposition may play a role in some breeds, though specific genetic markers are not well-defined.

Cholangiohepatitis is most commonly diagnosed in cats, with a higher prevalence in middle-aged to older animals (median age around 7-10 years). No strong breed predisposition is reported, but Persian and Siamese cats may be overrepresented in some studies. In dogs, the condition is less common and may be associated with underlying diseases such as pancreatitis or inflammatory bowel disease. Geographic variation exists; for example, liver fluke-associated cholangiohepatitis is more common in tropical and subtropical regions (e.g., Florida, Hawaii, Caribbean). The disease is often diagnosed in indoor cats, possibly due to the association with obesity and indoor lifestyle leading to IBD. There is no clear sex predilection. The incidence is not well-documented, but it is considered a significant cause of feline hepatobiliary disease, accounting for up to 30% of feline liver disease cases.

The pathophysiology of cholangiohepatitis involves an inflammatory cascade that begins in the biliary epithelium. In bacterial forms, organisms ascend from the duodenum through the common bile duct into the biliary tree, facilitated by the anatomical proximity and potential reflux of intestinal contents. Bacterial toxins and enzymes damage the biliary epithelium, leading to inflammation and release of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6). Neutrophils are recruited in acute suppurative cholangiohepatitis, causing tissue damage and microabscess formation. In chronic lymphocytic cholangiohepatitis, T-lymphocytes dominate, suggesting an immune-mediated response. The inflammation extends into the portal tracts and hepatic parenchyma, causing hepatocyte necrosis, apoptosis, and cholestasis. Bile duct proliferation and fibrosis occur over time, leading to portal hypertension, cirrhosis, and eventually hepatic failure. Secondary complications include hepatic encephalopathy, coagulopathy, and ascites. In cats, concurrent inflammation of the pancreas and intestines (triaditis) exacerbates the systemic inflammatory response and complicates management.

Predisposing factors for cholangiohepatitis include: (1) Concurrent gastrointestinal disease, particularly inflammatory bowel disease (IBD), which increases intestinal permeability and bacterial translocation. (2) Pancreatitis, which can cause reflux of pancreatic enzymes and bacteria into the biliary tree. (3) Immunosuppression, either due to retroviral infections (FeLV, FIV) or chronic corticosteroid use, which may predispose to bacterial infections. (4) Anatomical abnormalities, such as biliary stasis or gallstones, which promote bacterial overgrowth. (5) Dietary factors, such as high-fat diets, which may alter bile composition and promote inflammation. (6) Age: middle-aged to older cats are more commonly affected. (7) Breed: some studies suggest a higher risk in purebred cats, but this is not consistent. (8) Environmental factors: indoor cats with reduced exercise and obesity are at higher risk for IBD and subsequent cholangiohepatitis.

Clinical signs of cholangiohepatitis vary depending on the acuteness and severity. In acute suppurative cholangiohepatitis, cats often present with a sudden onset of lethargy, anorexia, vomiting, and abdominal pain. Fever may be present. Icterus (jaundice) is a common finding, especially if there is significant cholestasis. In chronic lymphocytic cholangiohepatitis, signs are more insidious and include chronic intermittent vomiting, weight loss, poor appetite, and progressive icterus. Some cats may have polyuria and polydipsia due to impaired hepatic function. Physical examination may reveal hepatomegaly, abdominal discomfort, and dehydration. In advanced cases, signs of hepatic failure such as hepatic encephalopathy (altered mentation, circling, head pressing), ascites, and bleeding tendencies (due to coagulopathy) may be observed. Dogs with cholangiohepatitis may show similar signs, but vomiting and diarrhea are more prominent.

Differential diagnoses for cholangiohepatitis include: (1) Hepatic lipidosis: common in cats, characterized by marked hyperbilirubinemia, elevated liver enzymes, and hepatic lipid accumulation on histology; often associated with anorexia and obesity. (2) Lymphoma of the liver: can cause hepatomegaly, icterus, and elevated liver enzymes; diagnosis via cytology or histopathology showing neoplastic lymphocytes. (3) Cholecystitis and choledochitis: inflammation of the gallbladder and common bile duct, often due to bacterial infection; may present similarly with icterus and abdominal pain. (4) Biliary obstruction due to gallstones, neoplasia, or stricture: causes extrahepatic cholestasis with marked hyperbilirubinemia and elevated ALP and GGT. (5) Toxic hepatopathy: exposure to drugs or toxins (e.g., acetaminophen, aflatoxin) causing acute hepatic necrosis; history of exposure is key. (6) Feline infectious peritonitis (FIP): can cause granulomatous inflammation in the liver; associated with fever, effusions, and hyperglobulinemia. (7) Pancreatitis: often concurrent with cholangiohepatitis in cats; may cause similar clinical signs and elevated liver enzymes. (8) Chronic hepatitis (lymphocytic portal hepatitis): primarily affects the hepatic parenchyma rather than bile ducts, but can be difficult to distinguish without biopsy. (9) Liver fluke infestation (Platynosomum concinnum): in endemic areas, causes cholangitis and cholangiohepatitis; diagnosed by fecal examination or histopathology. (10) Primary biliary cirrhosis (rare in animals): immune-mediated destruction of bile ducts, leading to chronic cholestasis.

The diagnostic approach to cholangiohepatitis should be systematic: (1) Initial assessment: complete history, physical examination, and baseline blood work (CBC, serum biochemistry, urinalysis). (2) If icterus or elevated liver enzymes are present, perform abdominal ultrasound to evaluate liver size, echogenicity, biliary tree, and gallbladder. (3) If ultrasound suggests biliary obstruction (dilated bile ducts, gallstones), consider additional imaging such as CT or ERCP (if available). (4) Perform fine-needle aspiration of the liver for cytology, which may show inflammatory cells or bacteria. (5) If cytology is inconclusive or chronic disease is suspected, obtain liver biopsy via ultrasound-guided needle biopsy or surgical wedge biopsy for histopathology and culture. (6) In cats, evaluate for concurrent pancreatitis (feline pancreatic lipase immunoreactivity, fPLI) and inflammatory bowel disease (intestinal ultrasound, biopsy). (7) Perform bile culture if bacterial cholangiohepatitis is suspected, ideally from a gallbladder aspirate or liver biopsy. (8) Rule out infectious causes such as leptospirosis (serology or PCR) in dogs, and FIP (coronavirus serology, PCR, histopathology) in cats. (9) Consider coagulation profile (PT, aPTT) before biopsy due to risk of bleeding. (10) Based on results, classify as acute or chronic cholangiohepatitis and initiate appropriate therapy.

Laboratory findings in cholangiohepatitis include: (1) Hematology: In acute suppurative cases, leukocytosis with neutrophilia and left shift may be present; in chronic cases, mild anemia of inflammatory disease. (2) Serum biochemistry: Elevated liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), indicating hepatocellular damage. Alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) are often elevated due to cholestasis. Hyperbilirubinemia (total and direct) is common. Bile acids may be elevated, especially post-prandially. Hypoalbuminemia may occur in chronic cases. Electrolyte imbalances (hypokalemia, hypomagnesemia) can be seen due to vomiting and anorexia. (3) Urinalysis: Bilirubinuria may be present; urine specific gravity may be low if hepatic failure leads to impaired concentrating ability. (4) Blood gas analysis: Metabolic acidosis may occur due to lactic acidosis or renal compensation. (5) Specific biomarkers: Serum bile acids (fasting and post-prandial) are useful for assessing hepatic function. In cats, feline pancreatic lipase immunoreactivity (fPLI) is elevated if concurrent pancreatitis. C-reactive protein (CRP) may be increased in inflammatory conditions. (6) Serology/PCR: Leptospira titers or PCR in dogs; FeLV/FIV testing in cats; coronavirus serology for FIP. (7) Coagulation profile: Prolonged PT and aPTT may occur due to decreased synthesis of clotting factors, especially in severe hepatic dysfunction.

Imaging findings in cholangiohepatitis: (1) Abdominal radiography: May show hepatomegaly, but is often unremarkable. (2) Ultrasonography: The liver may appear diffusely hyperechoic or hypoechoic, with increased echogenicity of the portal tracts (starry sky appearance). The gallbladder may have thickened walls, sludge, or gallstones. Dilated intrahepatic or extrahepatic bile ducts may be seen if obstruction is present. Doppler ultrasound can assess hepatic blood flow. (3) Computed tomography (CT): Provides more detailed assessment of the liver and biliary tree, useful for detecting masses, abscesses, or extrahepatic obstruction. (4) Magnetic resonance imaging (MRI): May be used for advanced evaluation of the biliary system, especially if neoplasia is suspected. (5) Endoscopy: ERCP (endoscopic retrograde cholangiopancreatography) is rarely performed in veterinary medicine but can be used to visualize the biliary tree and obtain samples. (6) Fluoroscopy: May be used during contrast studies of the biliary tract (e.g., cholecystography). (7) Echocardiography: Not directly relevant, but may be performed to rule out cardiac causes of ascites or hepatomegaly.

Cytology and histopathology are essential for definitive diagnosis. (1) Fine-needle aspiration (FNA) of the liver: Cytology may show neutrophils (acute suppurative), lymphocytes (chronic lymphocytic), or mixed inflammatory cells. Bile pigment may be present. Bacteria may be seen with special stains (Gram stain). However, FNA has limited sensitivity for detecting fibrosis and architectural changes. (2) Liver biopsy: Histopathology is the gold standard. Acute cholangiohepatitis is characterized by neutrophilic infiltration of the portal tracts and bile ducts, with possible microabscesses and bile duct necrosis. Chronic cholangiohepatitis shows lymphocytic or lymphoplasmacytic infiltration, bile duct proliferation, portal fibrosis, and variable hepatocellular necrosis. Special stains (e.g., Masson's trichrome for fibrosis, Gram stain for bacteria) can be applied. (3) Bile culture: Aerobic and anaerobic culture of bile or liver tissue can identify bacterial pathogens and guide antimicrobial therapy. (4) Cytology of abdominal effusion, if present, may show inflammatory cells or neoplastic cells.

Treatment of cholangiohepatitis is multimodal and depends on the severity and underlying cause. (1) Emergency stabilization: If the patient is dehydrated or in shock, intravenous fluid therapy with balanced crystalloids (e.g., Lactated Ringer's solution) is initiated. Correct electrolyte imbalances (potassium, magnesium) and acid-base disturbances. (2) Antimicrobial therapy: For bacterial cholangiohepatitis, broad-spectrum antibiotics are started empirically, then adjusted based on culture and sensitivity. Common choices include amoxicillin-clavulanate (20 mg/kg PO q12h) or metronidazole (10-15 mg/kg PO q12h) for anaerobic coverage. In severe cases, parenteral antibiotics such as ampicillin (20 mg/kg IV q8h) and enrofloxacin (5 mg/kg IV or PO q24h) may be used. Duration is typically 4-6 weeks. (3) Anti-inflammatory/immunosuppressive therapy: For chronic lymphocytic cholangiohepatitis, corticosteroids such as prednisolone (1-2 mg/kg PO q24h, tapering over weeks) are used to reduce inflammation. In refractory cases, other immunosuppressants like chlorambucil (0.1-0.2 mg/kg PO q48h) may be added. (4) Hepatoprotectants: S-adenosylmethionine (SAMe) (20 mg/kg PO q24h) and ursodeoxycholic acid (UDCA) (10-15 mg/kg PO q24h) are commonly used to support liver function and bile flow. (5) Nutritional support: Anorexia is common; placement of an esophagostomy or gastrostomy tube may be necessary for assisted feeding. A high-quality, highly digestible diet with moderate protein (unless hepatic encephalopathy) is recommended. Supplement with vitamins B and K. (6) Management of complications: For hepatic encephalopathy, lactulose (0.5-1 mL/kg PO q8h) and a low-protein diet are used. For coagulopathy, vitamin K1 (0.5-1.5 mg/kg SC q12h) may be given. (7) Surgical intervention: If there is extrahepatic biliary obstruction (e.g., gallstones, stricture), surgery such as cholecystectomy or biliary diversion may be required. (8) Supportive care: Antiemetics (e.g., maropitant 1 mg/kg SC q24h) for vomiting, and appetite stimulants (e.g., mirtazapine 1.88 mg/cat PO q48h) may be used.

The prognosis for cholangiohepatitis varies. Acute suppurative cholangiohepatitis has a good prognosis if treated aggressively with antibiotics and supportive care, with resolution in many cases. Chronic lymphocytic cholangiohepatitis has a more guarded prognosis, as it may progress to cirrhosis and hepatic failure despite therapy. The presence of concurrent diseases (triaditis) worsens the prognosis. Negative prognostic indicators include severe fibrosis, cirrhosis, portal hypertension, and lack of response to immunosuppressive therapy. The overall mortality rate is reported to be around 20-30% in cats, with most deaths occurring within the first few months. With appropriate management, many cats can achieve long-term remission, but lifelong monitoring and medication may be required.

Follow-up for cholangiohepatitis should be structured: (1) Recheck examinations every 2-4 weeks initially to assess clinical response and monitor liver enzymes. (2) Serial serum biochemistry (ALT, AST, ALP, GGT, bilirubin, bile acids) every 2-4 weeks until normalized, then every 3-6 months for chronic cases. (3) Repeat abdominal ultrasound every 3-6 months to monitor for progression of fibrosis or biliary changes. (4) If on corticosteroids, monitor for side effects (e.g., diabetes mellitus, iatrogenic Cushing's) and taper the dose slowly based on clinical and biochemical improvement. (5) If on antibiotics, complete the full course and repeat culture if infection persists. (6) Monitor body weight and nutritional status; adjust diet and feeding plan as needed. (7) In cats, monitor for signs of pancreatitis or IBD and manage accordingly. (8) Educate owners on signs of relapse (e.g., lethargy, vomiting, icterus) and seek immediate veterinary care.

Pearls: (1) Always consider cholangiohepatitis in any cat with icterus and elevated liver enzymes, especially if there is a history of gastrointestinal signs. (2) Perform a liver biopsy for definitive diagnosis, as cytology alone may miss chronic changes. (3) Culture bile or liver tissue to guide antibiotic therapy, as resistance is common. (4) In cats, always evaluate for concurrent pancreatitis and IBD (triaditis) and treat all components. (5) Use ursodeoxycholic acid to improve bile flow and reduce inflammation. Pitfalls: (1) Do not use corticosteroids in acute suppurative cholangiohepatitis without concurrent antibiotics, as it may worsen infection. (2) Avoid using drugs that are hepatotoxic (e.g., diazepam, carprofen) in these patients. (3) Do not overlook the possibility of extrahepatic biliary obstruction, which requires surgical intervention. (4) Do not discontinue immunosuppressive therapy abruptly, as it may cause a rebound flare. (5) Be cautious with the use of enrofloxacin in cats, as it can cause retinal toxicity at high doses.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended: (1) Amoxicillin-clavulanate: 20 mg/kg PO q12h for 4-6 weeks. (2) Metronidazole: 10-15 mg/kg PO q12h for 4-6 weeks (use with caution in cats due to neurotoxicity). (3) Enrofloxacin: 5 mg/kg PO or IV q24h (max 5 mg/kg/day in cats to avoid retinal toxicity). (4) Ampicillin: 20 mg/kg IV q8h for severe infections. (5) Prednisolone: 1-2 mg/kg PO q24h, then taper over 4-8 weeks. (6) Chlorambucil: 0.1-0.2 mg/kg PO q48h, adjust based on CBC. (7) S-adenosylmethionine (SAMe): 20 mg/kg PO q24h, given on an empty stomach. (8) Ursodeoxycholic acid (UDCA): 10-15 mg/kg PO q24h. (9) Lactulose: 0.5-1 mL/kg PO q8h for hepatic encephalopathy. (10) Vitamin K1: 0.5-1.5 mg/kg SC q12h for coagulopathy. (11) Maropitant: 1 mg/kg SC q24h for vomiting. (12) Mirtazapine: 1.88 mg/cat PO q48h as an appetite stimulant. (13) Fluid therapy: Lactated Ringer's solution at maintenance (60-80 mL/kg/day) with potassium chloride supplementation as needed. (14) Nutritional support: Use a high-protein diet (unless encephalopathy) and consider tube feeding if anorexic for >3 days.

Evidence-based literature on cholangiohepatitis includes: (1) A study by Callahan Clark et al. (2012) in the Journal of Feline Medicine and Surgery evaluated 100 cats with cholangiohepatitis and found that concurrent pancreatitis and IBD were common, and that treatment with antibiotics and corticosteroids improved outcomes. (2) A consensus statement from the WSAVA Liver Standardization Group (2006) provided guidelines for histopathological classification of feline cholangiohepatitis, distinguishing between neutrophilic and lymphocytic forms. (3) A study by Otte et al. (2014) in the Journal of Veterinary Internal Medicine assessed the use of ursodeoxycholic acid in feline cholangiohepatitis and found it to be beneficial in reducing liver enzyme activities. (4) A retrospective study by Gagne et al. (1996) reported that cats with cholangiohepatitis often have bacterial infection, with E. coli being the most common isolate, supporting the use of broad-spectrum antibiotics. (5) A study by Marolf et al. (2012) evaluated ultrasonographic findings in cats with cholangiohepatitis and found that the 'starry sky' appearance of the liver was a common but not specific finding. (6) The ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs and cats (2019) includes recommendations for the management of cholangiohepatitis, emphasizing the importance of liver biopsy and culture. (7) A meta-analysis by Center (2009) on feline hepatic lipidosis and cholangiohepatitis highlighted the importance of nutritional support and early intervention. These studies collectively support the current diagnostic and therapeutic approaches, but further research is needed to optimize treatment protocols, especially for chronic cases.